Oncopeptides AB

Chart & Performance

D1W1MN

P/E

—

P/S

5.38

EPS

—

Div Yield, %

—

Shrs. gr., 5y

29.47%

Rev. gr., 5y

0.00%

Revenues

71m

+124.72%

Net income

-250m

L-12.31%

CFO

-223m

L-14.46%

Notes

No notes on this company yet

Write a private note on this company, for your eyes only

Add note

Profile

Oncopeptides AB (publ) is a biotechnology company focused on developing pharmaceutical therapies to combat cancer. The firm's therapeutic innovations are intended for markets across the United States, Europe, and internationally. Its flagship product candidate, melflufen, is an advanced anti-cancer peptide drug conjugate specifically designed to treat adult patients afflicted with relapsed refractory multiple myeloma. Oncopeptides AB (publ) was founded in 2000 and is headquartered in Stockholm, Sweden.

URL

https://www.oncopeptides.se/

IPO date

Feb 22, 2017

Employees

Domiciled in

Incorporated in

Valuation

Order:

Title SEK in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title SEK in thousands, except ratios and share amounts	2025‑12	2024‑12	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT